網膜血管腫様増殖に対するベバシズマブまたはラニビズマブ併用光線力学的療法の比較

Photodynamic therapy for retinal angiomatous proliferation preceded by intravitreal bevacizumab or ranibizumab

要約　目的：網膜血管腫様増殖（RAP）に対するベバシズマブまたはラニビズマブの硝子体内投与を併用した光線力学療法の効果の報告。対象と方法：初回治療として光線力学療法を行ったRAP 24例26眼を対象とした。男性6眼，女性20眼で，年齢は69～91歳（平均79歳）である。光線力学療法の1週間前に，14眼にはベバシズマブ，12眼にはラニビズマブを硝子体内に投与した。結果：術後視力は改善し，両群間に有意差はなかった。治療から6か月以内の再発は，ベバシズマブ群では14眼中3眼（21％），ラニビズマブ群では12眼中8眼（67％）にあり，有意差があった（p＝0.02）。結論：RAPに対する光線力学療法1週間前のベバシズマブ硝子体中投与は，ラニビズマブ投与よりも6か月間の治療効果が高かった。

Abstract.　Purpose：To report the outcome of photodynamic therapy for retinal angiomatous proliferation（RAP）preceded by intravitreal bevacizumab or ranibizumab. Cases and Method：This retrospective study was made on 26 eyes of 24 patients who received photodynamic therapy for retinal angiomatous proliferation. The series comprised 6 male and 20 female eyes. The age ranged from 69 to 91,average 79 years. One week before photodynamic therapy,14 eyes received intravitreal bevacizumab and 12 eyes received ranibizumab. Results：Overall visual acuity improved after treatment. There was no difference between the two groups. RAP recurred in 3 out of 14 eyes（21％）that received bevacizumab and in 8 out of 12 eyes（67％）that received ranibizumab. The difference was significant（p＝0.02）. Conclusion：Intravitreal bevacizumab prior to photodynamic therapy for RAP was more effective than ranibizumab during 6 months after treatment.